LOGIN  |  REGISTER
Astria Therapeutics
Amneal Pharmaceuticals

CYduct Diagnostics Announces Participation in The Reg A & Crowdfunding Conference

May 22, 2024 | Last Trade: US$0.50 0.00 0.00

Westport, Connecticut--(Newsfile Corp. - May 22, 2024) - CYduct Diagnostics (OTC Pink: CYDX), CYductDX is a disruptive clinical-stage diagnostic company led by an experienced team of senior executives and scientists focused on proprietary technologies for the early assessment and detection of Breast Cancer., will be attending The Reg A & Crowdfunding Conference, which will take place on June 20 at the Westchester Country Club in Rye, New York.

Dom Gatto: President/CEO is open to taking meetings. Please reach out through the conference app to connect.

To register for the conference, please follow this link.

About CYduct Diagnostics

CYductDX headquartered in Westport, CT, is disrupting the breast cancer market by addressing the unmet clinical need for accurate risk assessment of breast cancer, particularly in women already at high-risk and those with dense breast tissue, so as to detect breast cancer at its earliest stages. In order to “Find It Early”, it is important to focus on the origin of virtually all breast cancers–The Mammary Ducts. The aim of CYduct is to provide specialized intraductal tools and processes that offer a suite of breast healthcare products which assess, screen, detect, monitor and treat early changes that distinguish variations in breast health. CYduct has a unique precision medicine test for women, coupled with advanced breast health medical devices for the evolutionary improvement in helping identify precancerous and cancerous lesions while still within the mammary ducts, offering the earliest detection of breast cancer.

About The Reg A & Crowdfunding Conference

The Reg A & Crowdfunding Conference is the largest annual gathering place for online investment platforms, brokers, legal and financial advisors, investors, and other dealmakers involved in Reg A and crowdfunding deals. This event is also well attended by private and public companies looking to raise capital using Reg A and Reg CF.

In 2024, the conference will broaden its focus to include Crowdfunding deals with more of the program dedicated to online deal-marketing tactics. Attendees will glean insight from experts on deal structures, fees and expenses, and the continuously changing regulatory landscape.

For further information:
Dom Gatto
President/CEO
(203) 915-7016
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page